ANDROGEN deprivation therapy (ADT) has been the cornerstone of treatment for advanced castration-sensitive prostate cancer ...

Androgen deprivation therapy (ADT) alone or in combination with radiation therapy or other drugs is increasingly used for the treatment of localized, high-risk, or biochemical relapse of prostate ...

About 12% of prostate cancer patients receiving androgen deprivation therapy underwent all recommended screening for treatment-related adverse events. Many prostate cancer patients receiving androgen ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Opens in a new tab or window In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

Triplet therapy using darolutamide vs abiraterone ... compared with abiraterone with prednisone and ADT only. “Androgen deprivation can modulate dopaminergic transmission; therefore, a previous ...

Artificial intelligence (AI)-based risk classification improves prognostication with localized prostate cancer, according to ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in ...

Androgen deprivation is the mainstay of therapy of advanced prostate cancer treatment, but the cure rate is low and patients eventually become castrate resistant. Castration-resistant prostate ...

Local radiation therapy added to ADT for mHSPC reduces the rate of adverse events such as bladder outlet obstruction and hydronephrosis. Adding local external beam radiation therapy (EBRT) to ...

Suggested remit: To appraise the clinical and cost effectiveness of darolutamide with androgen deprivation therapy within its marketing authorisation for treating hormone-sensitive metastatic prostate ...